Dr. Nayoung Han
My Social Links

Dr. Nayoung Han

Research Scientist
Chungnam National University, South Korea

Highest Degree
Ph.D. in Pharmacy from Seoul National University, Korea

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Drug Discovery
62%
Clinical Pharmacology
90%
Pharmacogenomics
75%
Pharmacotherapy
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Koo, H., S. Jang, J.M. Oh, N. Han and E. Han, 2016. Qualitative study for medication use among visually impaired in Korea. Korean J. Clin. Pharm., 26: 24-32.
    Direct Link  |  
  2. Kang, J.E., N.Y. Han, J.M. Oh, H.K. Jin, H.A. Kim, I.J. Son and S.J. Rhie, 2016. Pharmacist‐involved care for patients with heart failure and acute coronary syndrome: A systematic review with qualitative and quantitative meta‐analysis. J. Clin. Pharm. Therapeutics, 41: 145-157.
    CrossRef  |  Direct Link  |  
  3. Jeong, S., N. Han, B. Choi, M. Sohn and Y.K. Song et al., 2016. Construction of a database for published phase II/III drug intervention clinical trials for the period 2009-2014 comprising 2,326 records, 90 disease categories and 939 drug entities. Int. J. Clin. Pharmacol. Therapeutics, 54: 416-425.
    Direct Link  |  
  4. Jeong, S., J.H. Kim, M.G. Kim, N. Han, I.W. Kim, T. Kim and J.M. Oh, 2016. Genetic polymorphisms of CASR and cancer risk: Evidence from meta-analysis and HuGe review. OncoTargets Therapy, 9: 655-669.
    CrossRef  |  Direct Link  |  
  5. Jeong, S., I.W. Kim, K.H. Oh, N. Han, K.W. Joo, H.J. Kim and J.M. Oh, 2016. Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. Drug Design Dev. Therapy, 10: 2211-2225.
    CrossRef  |  Direct Link  |  
  6. Han, N., S.M. Lee, J.Y. Hong, H.J. Noh and E. Ji et al., 2016. Clinical outcomes of multidisciplinary team care on the regulation of chronic kidney disease-mineral and bone disorder (CKD-MBD) in patients undergoing dialysis. Korean J. Clin. Pharm., 26: 318-323.
    Direct Link  |  
  7. Choi, Y.J., Y.M. Ah, J. Kong, K.H. Choi and B. Kim et al., 2016. Implication of different initial beta blockers on treatment persistence: Atenolol vs new‐generation beta blocker, a population‐based study. Cardiovascular Therapeutics, 34: 268-275.
    CrossRef  |  Direct Link  |  
  8. Ah, Y.M., J.Y. Lee, Y.J. Choi, J. Kong and B. Kim et al., 2016. Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study. Clin. Exp. Hypertension, 38: 325-330.
    CrossRef  |  Direct Link  |  
  9. Sohn, H.S., H. Kim, H. Park, N. Han, J.M. Oh and E. Ji, 2015. Pharmaceutical care services of community pharmacies in korea through the review of literature. Korean J. Clin. Pharm., 25: 18-26.
    Direct Link  |  
  10. Kim, T., N. Han, M. Sohn, J.M. Oh, E.K. Lee, E. Ji and I.W. Kim, 2015. Pharmacogenomic biomarker information in FDA‐approved paediatric drug labels. Basic Clin. Pharmacol. Toxicol., 116: 438-444.
    CrossRef  |  Direct Link  |  
  11. Kim, M.G., N. Han, E.K. Lee and T. Kim, 2015. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: A systematic review and meta-analysis. Bone Marrow Transp., 50: 523-530.
    CrossRef  |  Direct Link  |  
  12. Kim, M.G., I.W. Kim, B. Choi, N. Han, H.Y. Yun, S. Park and J.M. Oh, 2015. Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: Consideration of genetic polymorphisms. Ann. Pharmacotherapy, 49: 622-630.
    CrossRef  |  Direct Link  |  
  13. Kim, I.W., N. Han, M.G. Kim, T. Kim and J.M. Oh, 2015. Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular and lung carcinoma using the cancer genome atlas data. Pharmacogen. Genom., 25: 1-7.
  14. Choi, B., M.G. Kim, N. Han, T. Kim and E. Ji et al., 2015. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. Pharmacogenomics, 16: 1585-1594.
    CrossRef  |  Direct Link  |  
  15. Cho, I.H., Y.K. Song, M.G. Kim, N. Han, T. Kim and J.M. Oh, 2015. Association between interleukin-10 promoter gene polymorphisms and acute graft-versus-host disease after hematopoietic stem cell transplantation: A systematic review and meta-analysis. Hematology, 20: 121-128.
    CrossRef  |  Direct Link  |  
  16. Kim, I.W., N. Han, G.J. Burckart and J.M. Oh, 2014. Epigenetic changes in gene expression for drug‐metabolizing enzymes and transporters. Pharm.: J. Hum. Pharmacol. Drug Therapy, 34: 140-150.
    CrossRef  |  Direct Link  |  
  17. Han, N., S. Ha, H.Y. Yun, M.G. Kim and S.I. Min et al., 2014. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin. Pharmacol. Toxicol., 114: 400-406.
    CrossRef  |  Direct Link  |  
  18. Han, N., H.Y. Yun, I.W. Kim, Y.J. Oh, Y.S. Kim and J.M. Oh, 2014. Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur. J. Clin. Pharmacol., 70: 1211-1219.
    CrossRef  |  Direct Link  |  
  19. Ahn, S.M., H. Kim, E. Ji, N. Han and J.M. Oh, 2014. The effect of orlistat on weight reduction in obese and overweight Korean patients. Arch. Pharm. Res., 37: 512-519.
    CrossRef  |  Direct Link  |  
  20. Kim, I.W., H.Y. Yun, B. Choi, N. Han, M.G. Kim, S. Park and J.M. Oh, 2013. Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur. J. Clin. Pharmacol., 69: 1543-1551.
    CrossRef  |  Direct Link  |  
  21. Han, N., H.Y. Yun, J.Y. Hong, I.W. Kim and E. Ji et al., 2013. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur. J. Clin. Pharmacol., 69: 53-63.
    CrossRef  |  Direct Link  |  
  22. Song, J., M.G. Kim, B. Choi, N.Y. Han, H.Y. Yun, J.H. Yoon and J.M. Oh, 2012. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: Analysis by population pharmacokinetics. Ann. Pharmacotherapy, 46: 1141-1151.
  23. Kim, S.M., E. Ji, H. Kim, N. Han and M. Shim et al., 2012. Efficacy of acipimox in comparison with fenofibrate for hypertriglyceridemia. Korean J. Clin. Pharm., 22: 195-201.
    Direct Link  |  
  24. Kim, I.W., Y.J. Moon, E. Ji, K. Im Kim and N. Han et al., 2012. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur. J. Clin. Pharmacol., 68: 657-669.
    CrossRef  |  Direct Link  |  
  25. Kim, I.W., H.Y. Yun, B. Choi, N. Han, S.Y. Park, E.S. Lee and J.M. Oh, 2012. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: A prospective analysis. Clin. Therapeutics, 34: 1816-1826.
    CrossRef  |  Direct Link  |  
  26. Kim, I.W., H. Noh, E. Ji, N. Han and S.H. Hong et al., 2012. Identification of factors affecting tacrolimus level and 5‐Year clinical outcome in kidney transplant patients. Basic Clin. Pharmacol. Toxicol., 111: 217-223.
    CrossRef  |  Direct Link  |  
  27. Ji, E., L. Choi, K.S. Suh, J.Y. Cho, N. Han and J.M. Oh, 2012. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation, 94: 866-872.
    CrossRef  |  Direct Link  |  
  28. Ji, E., H.Y. Park, H. Noh, D.E. Lee and N. Han et al., 2012. Development of contents for KFDA drug safety information website. Yakhak Hoeji, 56: 204-209.
  29. Lee, S.M., B. Choi, H.Y. Yun, D.H. Jun and M.G. Kim et al., 2011. Strategic plans for the implementation of pharmacometric methodology in drug regulatory review decisions. Korean J. Clin. Pharm., 21: 339-346.
    Direct Link  |  
  30. Ji, E.H., J.E. Park, N.Y. Han, J.Y. Hong and H.J. Noh et al., 2010. Development of the information materials on vaccine's safety and adverse events. Korean J. Clin. Pharm., 20: 55-65.